Predominance of Th1 Immune Response in Diffuse Proliferative Lupus Nephritis

Arthritis and Rheumatism

Volumn 44, Issue 9, 2001, Pages 2097-2106

  Masutani, Kohsuke ^a   Akahoshi, Mitsuteru ^a   Tsuruya, Kazuhiko ^a   Tokumoto, Masanori ^a   Ninomiya, Toshiharu ^a   Kohsaka, Tsutomu ^b   Fukuda, Kyoichi ^a   Kanai, Hidetoshi ^a   Nakashima, Hitoshi ^a   Otsuka, Takeshi ^a   Hirakata, Hideki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Otsuka Tokyo Assay Laboratories   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD68 ANTIGEN, HUMAN; CD8 ANTIGEN; DIFFERENTIATION ANTIGEN; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; OSTEOPONTIN; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOPSY; CHEMISTRY; FEMALE; GLOMERULUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY DISTAL TUBULE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MIDDLE AGED; PATHOLOGY; TH1 CELL; TH2 CELL;

ADULT; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD40; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; LUPUS NEPHRITIS; MALE; MIDDLE AGED; OSTEOPONTIN; SIALOGLYCOPROTEINS; TH1 CELLS; TH2 CELLS;

EID: 0038038551     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6     Document Type: Article

References (44)

1. Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995;144:157-93.
2. Kashgarian M. Lupus nephritis: pathology, pathogcncsis, clinical correlations, and prognosis. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997, p. 1037-51.
3. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
4. Prete GD. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol 1998;16:427-55.
5. Röcken M, Racke M, Shevach EM. IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 1996;17:225-31.
6. H2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. Immunol Today 1991;12:223-7.
7. Takahashi S, Fossati L, Iwamoto M, Merino R, Motta R, Kobayakawa T, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest 1996;97:1597-604.
8. Haas C, Ryffel B, Hir ML. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997;158:5484-91.
9. Peng SL, Moslchi J, Craft J. Roles of interferon-γ and interleukin-4 in murine lupus. J Clin Invest 1997;99:1936-46.
10. Balomenos D, Rumold R, Theofilopoulos AN. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998;101:364-71.
11. 1pr mice. J Immunol 1999;163:6884-91.
12. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993;13:58-67.
13. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999;42:1644-8.
14. Churg J, Bernstein J, Glassock RJ. Lupus nephritis. In: Churg J, Bernstein J, Glassock RJ, editors. Renal disease: classification and atlas of glomerular diseases. New York: Igaku-Shoin; 1995. p. 151-80.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Jung T, Schauer U, Hausser C, Neumann C, Reigers C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993;159:197-207.
17. Picker U, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-19.
18. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 1998;34:207-15.
19. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25: 689-95.
20. Furusu A, Miyazaki M, Koji T, Abe K, Ozono Y, Harada T, et al. Involvement of IL-4 in human glomerulonephritis: an in situ hybridization study of IL-4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol 1997;8:730-41.
21. Segerer S, Mack M, Regele H, Kerjaschki D, Schlöndorff D. Expression of C-C chemokine receptor 5 in human kidney disease. Kidney Int 1999;56:52-64.
22. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-5.
23. Martin M, Schwinzer R, Schellekens H, Resch K. Glomerular mesangial cells in local inflammation: induction of the expression of MHC class II antigens by IFN-gamma. J Immunol 1989;142: 1887-94.
24. Jevnikar AM, Wuthrich RP, Takei F, Xu HW, Brennan DC, Glimcher LH, et al. Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. Kidney Int 1990;38: 417-25.
25. Kuroiwa T, Lee EG. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 1998;7:597-603.
26. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulone-phritis, membranous nephropathy, and lupus nephritis. Kidney Int 1997;51:270-6.
27. Lan HY, Paterson DJ, Atkins RC. Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulone-phritis. Kidney Int 1991;40:425-33.
28. Segerer S, Nelson PJ, Schlöndorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11:152-76.
29. Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J Immunol 1999;163:2168-75.
30. Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A, et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988;34:511-7.
31. Ichiryu MS, Magil AB. Intraglomerular monocyte infiltration and immune deposits in diffuse lupus glomerulonephritis. Am J Kidney Dis 1999;33:866-71.
32. Hudkins KL, Giachelli CM, Eitner F, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int 2000;57:105-16.
33. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-82.
34. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, et al. Tubulointerstitial disease in glomeruloneprhritis: potential role of osteopontin (uropontin). Am J Pathol 1994; 144:915-26.
35. Lan XY, Yu WQ, Yang N, Nikolic-Paterson DJ, Mu W, Pichler R, et al. De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. Kidney Int 1998;53:136-45.
36. 1pr mice with lupus nephritis. Autoimmunity 1998;28: 139-50.
37. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287: 860-4.
38. O'Regan AW, Nau GJ, Chupp GL, Lowry JA, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000;21:475-8.
39. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-γ and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000;68:495-502.
40. Yellin MJ, D'Agati V, Parkinson G, Han AS-Y, Szema A, Baum D, et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997;40:124-34.
41. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97: 2063-73.
42. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
43. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
44. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.